ACE2 inhibition leads to pulmonary fibrosis (Homo sapiens)

From WikiPathways

Revision as of 13:25, 28 February 2023 by Marvin M2 (Talk | contribs)
Jump to: navigation, search
Bradykinin system, hyperactivatedKE1740: ACE2 inhibitionIncreased, secretion of proinflammatory and profibrotic mediatorsRenin Angiotensin Aldosterone SystemMetabolism of Angiotensinogen to AngiotensinsBradykinin receptor B1 activationNF-KB pathwayBradykinin signaling networkIncreased, Reactive oxygen speciesOxidative stressIncrease activation, Nuclear factor kappa B (NF-kB)Prostaglandin signalingKE1752: Increased Angiotensin IIKE1743: Increased plasma Angiotensin IIKE68: Collagen AccumulationKE1276: Lung FibrosisCollagen biosynthesis and modifying enzymesBinding of agonist, Angiotensin II receptor type 1 receptor (AT1R)Angiotensin II receptor type 1 pathwayACE2 inhibitionIncreased, Prostaglandin E2 secretionKinin-Kallikrein PathwayOverview of proinflammatory and profibrotic mediators


Description

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

  1. Clerbaux LA, Amigó N, Amorim MJ, Bal-Price A, Batista Leite S, Beronius A, Bezemer GFG, Bostroem AC, Carusi A, Coecke S, Concha R, Daskalopoulos EP, De Bernardi F, Edrosa E, Edwards SW, Filipovska J, Garcia-Reyero N, Gavins FNE, Halappanavar S, Hargreaves AJ, Hogberg HT, Huynh MT, Jacobson D, Josephs-Spaulding J, Kim YJ, Kong HJ, Krebs CE, Lam A, Landesmann B, Layton A, Lee YO, Macmillan DS, Mantovani A, Margiotta-Casaluci L, Martens M, Masereeuw R, Mayasich SA, Mei LM, Mortensen H, Munoz Pineiro A, Nymark P, Ohayon E, Ojasi J, Paini A, Parissis N, Parvatam S, Pistollato F, Sachana M, Sørli JB, Sullivan KM, Sund J, Tanabe S, Tsaioun K, Vinken M, Viviani L, Waspe J, Willett C, Wittwehr C; ''COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop.''; ALTEX, 2022 PubMed Europe PMC Scholia
  2. Wittwehr C, Amorim MJ, Clerbaux LA, Krebs C, Landesmann B, Macmillan DS, Nymark P, Ram R, Garcia-Reyero N, Sachana M, Sullivan K, Sund J, Willett C; ''Understanding COVID-19 through adverse outcome pathways - 2nd CIAO AOP Design Workshop.''; ALTEX, 2021 PubMed Europe PMC Scholia
  3. Nymark P, Sachana M, Leite SB, Sund J, Krebs CE, Sullivan K, Edwards S, Viviani L, Willett C, Landesmann B, Wittwehr C; ''Systematic Organization of COVID-19 Data Supported by the Adverse Outcome Pathway Framework.''; Front Public Health, 2021 PubMed Europe PMC Scholia

History

View all...
CompareRevisionActionTimeUserComment
125622view20:00, 5 March 2023AlexanderPicoModified description
125577view13:33, 28 February 2023Marvin M2Replaced 2 Event notes with labels since these do not exist in AOP-Wiki
125576view13:28, 28 February 2023Marvin M2Added references
125575view13:25, 28 February 2023Marvin M2Ontology Term : 'CL:0000057' removed !
118508view09:17, 28 May 2021FinterlyReplace DataNode Type "Key Event" with "Event"
116869view20:52, 14 May 2021Marvin M2Added KE pathway and connected line
116321view11:36, 30 April 2021Marvin M2added KE pathways
116261view12:51, 22 April 2021Marvin M2added chain of bradykinin and prostaglandin
116260view11:17, 22 April 2021Marvin M2corrected WP IDs
116232view14:38, 21 April 2021Marvin M2Ontology Term : 'fibroblast' added !
116231view14:38, 21 April 2021Marvin M2Ontology Term : 'angiotensin II signaling pathway via AT1 receptor' added !
116230view14:36, 21 April 2021Marvin M2Ontology Term : 'pulmonary fibrosis' added !
116229view14:36, 21 April 2021Marvin M2Ontology Term : 'COVID-19' added !
116227view13:16, 21 April 2021Marvin M2
116226view13:15, 21 April 2021Marvin M2typo in database
116225view13:15, 21 April 2021Marvin M2
116224view13:10, 21 April 2021Marvin M2Added KEs for AOP382
114326view08:52, 7 January 2021Marvin M2
114325view08:51, 7 January 2021Marvin M2
114321view17:37, 6 January 2021Marvin M2New pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
ACE2 inhibitionPathwayWP554 (WikiPathways)
Angiotensin II receptor type 1 pathwayPathwayWP5036 (WikiPathways)
Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R)Event1851 (AOP-Wiki KE)
Bradykinin receptor B1 activation
Bradykinin signaling networkPathwayWP5068 (WikiPathways)
Bradykinin system, hyperactivated1867 (AOP-Wiki KE)
Collagen biosynthesis and modifying enzymesPathwayWP2725 (WikiPathways)
Increase activation, Nuclear factor kappa B (NF-kB)Event1172 (AOP-Wiki KE)
Increased, Prostaglandin E2 secretion1 (AOP-Wiki KE)
Increased, Reactive oxygen speciesEvent1115 (AOP-Wiki KE)
Increased, secretion of proinflammatory and profibrotic mediators1496 (AOP-Wiki KE)
KE1276: Lung FibrosisEvent1276 (AOP-Wiki KE)
KE1740: ACE2 inhibitionEvent1740 (AOP-Wiki KE)
KE1743: Increased plasma Angiotensin IIEvent1743 (AOP-Wiki KE)
KE1752: Increased Angiotensin IIEvent1752 (AOP-Wiki KE)
KE68: Collagen AccumulationEvent68 (AOP-Wiki KE)
Kinin-Kallikrein PathwayPathwayWP5089 (WikiPathways)
Metabolism of Angiotensinogen to AngiotensinsPathwayWP2729 (WikiPathways)
NF-KB pathwayPathwayWP4562 (WikiPathways)
Overview of proinflammatory and profibrotic mediatorsPathwayWP5095 (WikiPathways)
Oxidative stressPathwayWP408 (WikiPathways)
Prostaglandin signalingPathwayWP5088 (WikiPathways)
Renin Angiotensin Aldosterone SystemPathwayWP4756 (WikiPathways)

Annotated Interactions

No annotated interactions

Retrieved from "https://classic.wikipathways.org/index.php/Pathway:WP5035"
Personal tools